The Diagnostic and Statistical Manual of Mental Disorders (DSM) published by the American Psychiatric Association provides a common language and standard criteria for the classification of mental disorders. It is used in the United States and in varying degrees around the world, by clinicians, researchers, psychiatric drug regulation agencies, health insurance companies, pharmaceutical companies, and policy makers. The current version is the DSM-IV-TR (fourth edition, text revision).
- Percent of DSM-IV task force members who had drug company ties: 57%
- Percent of those now working on DSM-V who have drug company ties: 69%
- Percent of current work groups in which most members have drug company ties: 75%
It is also noteworthy that, as with the DSM-IV, the most conflicted panels are those for which pharmacological treatment is the first-line intervention.
Percent of members that “have ties to the pharmaceutical companies that manufacture the medications used to treat these disorders or to companies that service the pharmaceutical industry” on the
- Mood disorders panel: 67%
- Psychotic disorders panel: 83%
- Sleep/wake disorders panel: 100%